Bayer’s Q1 Profit Returns to €2.8 Billion but Legal Bills Trigger €2.3 Billion Cash Outflow
18.05.2026 - 08:41:46 | boerse-global.de
Bayer shares ended last week at €37.72, trimming a year-to-date gain of roughly 64% after sliding more than 8% over the past month. The retreat comes despite a sharp improvement in earnings, as investors weigh operational momentum against the persistent drag from U.S. litigation costs.
Revenue in the three months through March rose 4.1% on a currency- and portfolio-adjusted basis to €13.4 billion. Adjusted earnings before interest, taxes, depreciation and amortisation climbed 9% to €4.45 billion, while net profit hit €2.8 billion — a dramatic swing from the net loss recorded in the same period last year. Earnings per share on an adjusted basis reached €2.71.
The main engine of the rebound was the Crop Science division, which accounted for about €21.6 billion of full-year 2025 revenue. Pharma earnings retreated, and Consumer Health contributed roughly €5.8 billion. Yet the operating strength is overshadowed by free cash flow of minus €2.3 billion, driven by heavy payments related to PCB and glyphosate lawsuits. Management continues to hold its currency-adjusted guidance for the full year.
Should investors sell immediately? Or is it worth buying Bayer?
Bayer’s wider competitive environment remains challenging. European chemical producers face gas prices around three times higher than in the U.S., and Chinese rivals have steadily expanded capacity since 2022, squeezing margins. The company’s pharma segment also confronts looming patent expiries that could pressure revenue later in the decade.
On the regulatory front, Bayer sought to bolster transparency by publishing the sixth edition of its neonicotinoid report on 16 May. The document outlines bee protection measures, evolving regulations and the agricultural role of insecticides such as imidacloprid, clothianidin and acetamiprid. A new early-stage screening for pollinator toxicity has been added to R&D processes. While neonicotinoids face severe restrictions in Europe, they remain widely used in the U.S., Brazil and India. Bayer highlights technical safeguards — polymer seed coatings and deflectors on planters — as measures to limit environmental exposure.
The report serves as a strategic communication tool at a time when regulatory pressure is tightening in several key markets. Analysts watching the stock see further upside: the average price target stands at €48.58, with fair value models pegging the equity at around €40. The shares currently trade just below their 50-day moving average.
The investment case for 2026 hinges on two variables: the trajectory of glyphosate-related cash outflows and the impact of patent losses in pharma. For now, the company is betting that its agriculture-led recovery can absorb the legal bills while it navigates a harsh European industrial backdrop.
Ad
Bayer Stock: New Analysis - 18 May
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Bayer’s Aktien ein!
FĂĽr. Immer. Kostenlos.
